AltaThera Pharmaceuticals

We're excited to be attending Heart Rhythm Society's #HRS2024 in Boston! If you're attending, stop by booth 763 and learn how a 1-hour loading dose of Sotalol IV may potentially shorten patient length of stay and increase bed availability at hospitals.* (We'll also have coffee☕) Interested in learning more about Sotalol IV while at the conference? Attend the May 17 poster presentation, “Correlation of Mobile ECG with 12-Lead ECG Findings During Intravenous Sotalol Loading for Atrial Fibrillation”, authored by Benjamin A. Steinberg, MD, MHS et al. at the Abstract Pavilion. For more information about this poster and the conference program, please visit the Heart Rhythm 2024 website at https://heartrhythm.com. See you in Boston! *Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 09/2023. WARNING: Life Threatening Proarrhythmia. Please see Sotalol IV Highlights of Prescribing Information and full Prescribing Information at https://lnkd.in/dT-ayk23, including boxed warning, contraindications, and dosing. 

Are you attending American College of Cardiology's ACC.24 in Atlanta? Be sure to stop by booth 1809 and learn how a 1-hour loading dose of Sotalol IV may potentially shorten patient length of stay and increase bed availability at hospitals.* ACC.24 attendees will be able gain insight into one health system’s experience with Sotalol IV by attending the April 6 poster presentation, “Real-World Comparative Effectiveness and Safety of Intravenous to Oral Sotalol Loading Among Patients with Atrial Arrhythmias”, authored by Keturah Weaver, PharmD, BCPS, Benjamin Heikkinen, PharmD, BCIDP, and Melinda Novak, PharmD. For more information about this poster and the conference program, please visit the ACC.24 website at https://lnkd.in/gkrcJVn. See you in Atlanta! #acc2024 #acc24 *Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 09/2023.  WARNING: Life Threatening Proarrhythmia. Please see Sotalol IV Highlights of Prescribing Information and full Prescribing Information at sotaloliv.com/pi, including boxed warning, contraindications, and dosing. 

At AF Symposium 2024, we sat down with T. Jared Bunch, MD to discuss trends in atrial fibrillation, practice patterns in usage of intravenous sotalol at the University of Utah and across the country, and more. Tune in and listen in on this insightful conversation! https://lnkd.in/g6Fmi5Pk

We're looking forward to seeing you at #AFSymposium2024 in Boston! Visit us in booth 503 and learn how a 1-hour Sotalol IV loading dose can help treat your patients with Atrial Fibrillation, Atrial Flutter, or Ventricular Tachycardia.* For more clinical data on Sotalol IV, attend Dr. T. Jared Bunch's  presentation, “IV Sotalol for Atrial Fibrillation—Insights from the PEAKS Registry” at 8:30 am on Thursday, February 1 (Spotlight Session I – New and Emerging Technologies in Arrhythmia Management).  Dr. Bunch is currently the section chief of electrophysiology at the University of Utah and is a Professor of Medicine. A graduate of the University of Utah School of Medicine, Dr. Bunch completed internal medicine residency at the Mayo Clinic. He completed fellowships in cardiovascular diseases and electrophysiology at the Mayo Clinic and served as an Assistant Professor of Medicine at the Mayo Clinic from 2003-08. He joined the cardiovascular team at Intermountain Heart Institute in 2008, directed heart rhythm research and served as medical director of heart rhythm services from 2010-19. The recipient of numerous accolades throughout his career, Dr. Bunch was an Affiliated Clinical Associate Professor for Stanford University from 2015-19 while at Intermountain. See you in Beantown! afsymposium.com #AFSymposium24 *Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 09/2023.  WARNING: Life Threatening Proarrhythmia. Please see Sotalol IV Highlights of Prescribing Information and full Prescribing Information at sotaloliv.com/pi, including boxed warning, contraindications, and dosing.